Psoriatic Arthritis Synovial Fluid

About Psoriatic Arthritis Synovial Fluid

Psoriatic Arthritis Synovial Fluid for Inflammatory Joint Disease Research

Psoriatic Arthritis Synovial Fluid is aspirated by licensed clinicians from IRB-consented donors with clinically confirmed psoriatic arthritis (PsA). Samples are collected under aseptic conditions and, where frozen material is requested, frozen within 4 hours of collection. Volumes are reported per lot. These specimens provide direct access to the inflamed joint compartment for research into immune-mediated synovitis, enthesitis-associated joint damage, and treatment response.

Why Synovial Fluid for Psoriatic Arthritis Research

Psoriatic arthritis is an immune-mediated inflammatory arthritis within the spondyloarthritis family. It is characteristically seronegative — rheumatoid factor and anti-citrullinated protein antibodies are typically absent, which is one of the features that separates PsA from rheumatoid arthritis — and the dominant pathway is innate and type 17 inflammation rather than autoantibody-driven autoimmunity. Synovial fluid samples that biology where it actually occurs.

• Synovial fluid is the fluid phase in immediate contact with inflamed synovium and cartilage, so cytokines, chemokines, and matrix degradation products are present at concentrations far above those in peripheral blood, where they are diluted below assay sensitivity.
• The IL-23/IL-17 axis is central to PsA, and synovial fluid permits direct measurement of IL-17A, IL-23, TNF, and downstream mediators at the disease site — the pathway targeted by IL-17, IL-23, and TNF inhibitors.
• PsA synovial fluid is characteristically neutrophil-rich, consistent with the prominent innate and IL-17-driven component, and this cellular profile differs from that of other inflammatory arthritides.
• The joint-infiltrating leukocyte population recovered from fluid is phenotypically distinct from circulating cells in the same donor, allowing tissue-resident and recruited populations to be characterised.
• PsA involves the synovio-entheseal complex, and cartilage and bone turnover markers released into synovial fluid support research into structural damage and new bone formation.
• Aspirate analysis also allows crystal-driven and degenerative arthropathies to be distinguished from immune-mediated synovitis, which matters for cohort purity in comparative studies.

Donor Stratification Available

• Clinical pattern: oligoarticular, polyarticular, distal interphalangeal-predominant, axial involvement, or arthritis mutilans
• Concurrent skin and nail psoriasis, including extent and nail involvement where documented
• Presence of enthesitis or dactylitis
• Serology: documented rheumatoid factor and ACPA status, and HLA-B27 where available
• Treatment status: biologic-naive, NSAID, conventional DMARD (methotrexate), TNF inhibitor, IL-17 inhibitor, IL-23 inhibitor, JAK inhibitor, or apremilast
• Joint aspirated, disease duration, and recorded disease activity assessment
• Matched healthy controls available, along with paired blood specimens from the same donor

Product Features

• Research Use Only (RUO), fresh or frozen synovial fluid
• Samples are frozen (if requested) within 4 hours of collection
• Clinically confirmed psoriatic arthritis donors
• Collected by licensed clinicians under aseptic conditions
• Processed and shipped same-day where applicable
• IRB-approved protocols and electronic informed consent
• Volumes reported per lot; paired plasma or serum available on request

De-identified Donor Data

• Verified diagnosis of psoriatic arthritis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and affected joints
• Disease activity and clinical history available upon request

Applications

• Cellular and cytokine profiling of the joint compartment, including IL-17 and TNF pathway readouts
• Immunophenotyping of synovial fluid neutrophils, T cells, and monocytes by flow cytometry
• Single-cell RNA sequencing of joint-infiltrating leukocytes
• Proteomic and metabolomic characterisation of inflamed synovial fluid
• Cartilage and bone turnover marker measurement for structural damage research
• Target validation and mechanism-of-action work for IL-17, IL-23, TNF, and JAK-directed therapeutics
• Comparative studies against rheumatoid arthritis and osteoarthritis synovial fluid
• Biomarker discovery for disease activity, flare, and treatment response

Other Psoriatic Arthritis Specimen Types

• Psoriatic Arthritis Serum
• Psoriatic Arthritis Plasma
• Psoriatic Arthritis Whole Blood
• Psoriatic Arthritis PBMC
• Psoriatic Arthritis Leukopak
• Psoriatic Arthritis Skin Punch Biopsy
• Psoriatic Arthritis Bulk Plasma

Compliance and Quality Assurance

• IRB-approved collections and SOP-driven processing
• 21 CFR Part 11-compliant electronic informed consent
• HIPAA-compliant donor data management

Ordering & Customization

Psoriatic Arthritis Synovial Fluid samples can be shipped ambient, refrigerated, or on dry ice. For pricing, availability, orders outside the United States, or regulatory documentation, please contact learnmore@sanguinebio.com. To browse other disease states and collection formats, visit our human synovial fluid page.